The European healthcare technology sector has entered a protracted period of structural realignment, precipitated by the breakdown of the historical venture capital funding escalator. Between 2020 and 2021, zero-interest-rate monetary policies and temporary pandemic tailwinds channeled speculative capital into early-stage digital health platforms, creating inflated entry valuations and subsidising unsustainable operational burn rates.

Macroeconomic analyses articulated by Bridgewater Associates founder Ray Dalio identify an impending structural inflection across the artificial intelligence landscape: the transition of capital allocation from equity-financed experimentation to debt fuelled physical infrastructure deployment. Industry projections indicate that global capital expenditures for artificial intelligence infrastructure will exceed $795 Billion in 2026 and cross $1 Trillion by 2027.

Lanas has entered into a definitive agreement to acquire the primary care software platform indici, committing NZ$150 million over a two year deployment schedule to accelerate its digital health footprint across New Zealand. This capital injection forms part of a multi year expansion program that lifts the group's aggregate enterprise investment in the domestic market toward NZ$200 Million. Formed in late 2025 following the acquisition of Clanwilliam Group by founder and Chie

The convergence of biopharmaceuticals and consumer health technology reached an institutional milestone with Eli Lilly and Company’s disclosed interest in purchasing up to $100 million in common stock during the initial public offering of Oura Inc.. Lined up alongside an indicated cornerstone commitment of up to $300 million from Dragoneer Investment Group, the joint commitments represent approximately $400 million, or nearly 19% of the wearable maker’s public offering.

The capitalisation trajectory of OpenEvidence represents one of the most compressed liquidity ascents in the enterprise healthcare technology sector. Within four years of its initial backing, the company evolved from an early-stage clinical retrieval experiment into a decacorn entity valued among the largest private software companies in the world. Between early 2025 and late 2026, OpenEvidence executed a series of high-velocity funding rounds that drove an aggregate fifteenf

The primary client profile for Nelson Advisors comprises clinically originated or founder-led enterprises generating annual revenues between €5 Million and €50 Million, operating EBITDA from €1 Million to €10 Million, and maintaining head counts of 20 to 250 personnel. These organisations typically possess established, scalable technologies but lack in-house corporate development infrastructure to navigate institutional M&A processes, cross-border regulatory hurdles, and comp